Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report

Authors: Chengcheng Guo, Qunying Yang, Jiawei Li, Shaoxiong Wu, Meiling Deng, Xiaojing Du, Ke Sai, Xiaobing Jiang, Zhenghe Chen, Ji Zhang, Fuhua Lin, Jian Wang, Yinsheng Chen, Chao Ke, Xiangheng Zhang, Xue Ju, Yonggao Mou, Jeffrey Bacha, Anne Steino, Sarath Kanekal, Claire Kwan, Gregory Johnson, Richard Schwartz, John Langlands, Dennis Brown, Zhong-ping Chen

Source: Glioma, Vol 2, Iss 4, Pp 167-173 (2019)

Subject Terms: adjuvant, chemotherapy, dianhydrogalactitol, glioblastoma multiforme, o-6-methylguanine-dna methyltransferase, phase 2, stupp regimen, temozolomide, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.jglioma.com/article.asp?issn=2589-6113;year=2019;volume=2;issue=4;spage=167;epage=173;aulast=Guo; https://doaj.org/toc/2589-6113; https://doaj.org/toc/2589-6121

Access URL: https://doaj.org/article/359acf2023e44c0588f664d99a97141b